MDT
Medtronic
$79.27
▼ 0.1%Updated Today 7:15 PM ET
▼ Down 7.5% over the last 12 months
Market Cap
$101.86B
P/E
21.2x
Forward P/E (est.)
20.57x
ROE
9.5%
Revenue Growth
8.4%
EPS Growth
3.1%
Profit Margin
13.2%
FCF Yield
5.9%
Debt / Equity
0.59x
ROIC
7.0%
Interest Coverage
8.28x
Current Ratio
2.54x
Dividend Yield
3.6%
Implied Growth (rev. DCF)
3.7%
Rating Score
55/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what MDT's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. MDT trades near $79.27, below its 50-day average ($80.14) and 200-day average ($91.91). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 65 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. MDT's is $2.08 (~2.6% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month MDT found buyers near $73.31 (support) and sellers near $82.83 (resistance); its 52-week range is $73.31–$106.33. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.8× the 20-day average — heavier than usual, which adds conviction to the move. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Medtronic (MDT) is a large-cap company in the Health Care Equipment industry, part of the Health Care sector of the S&P 500, with a market value around $101.86B.
In its latest reported year it generated about $33.54B in revenue and $4.66B in net profit.
Our model rates MDT Neutral (55/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
2.7%
Revenue moved from $30.12B in 2021 to $33.54B in 2025, a 2.7% compound annual growth rate. The most recent year grew a steady 8.4% year over year. Slower, mature growth is common for established businesses.
Gross Margin
65.3%
Operating Margin
17.8%
Net Margin
13.9%
ROE
9.5%
Medtronic keeps about 13.2% of each sales dollar as net profit, with a 65.3% gross margin and 17.8% operating margin. Return on equity is 9.5% and return on invested capital about 7.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$24.92B
Net Debt
$23.77B
Net Debt / EBITDA
3.99x
Debt / Equity
0.59x
Leverage: debt-to-equity is 0.6x, and operating profit covers interest about 8.3x, with a current ratio of 2.5x. That is a moderate, manageable debt load for most businesses. It carries roughly $24.92B of total debt against $1.15B of cash.
Operating CF
$7.04B
Free Cash Flow
$5.18B
FCF Margin
15.5%
In the latest year Medtronic produced about $7.04B of operating cash flow and $5.18B of free cash flow after capital spending. That is a free-cash-flow yield of about 5.9% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
21.2x
P/S
2.87x
P/B
2.19x
EV / EBITDA
14.22x
MDT trades at 21.2x trailing earnings (about 20.6x on estimated forward earnings), 2.9x sales, and 2.2x book value. Reverse-engineering today's price implies the market expects roughly 3.7% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How MDT stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), MDT ranks #26 of 59 by our overall rating. It trades at a discount versus the sector on earnings (21.2x P/E vs. 25.4x median) with a lower return on equity (9.5% vs. 14.9%) and faster revenue growth (8.4% vs. 7.9%).
P/E vs sector
21.2x
median 25.4x
ROE vs sector
9.5%
median 14.9%
Growth vs sector
8.4%
median 7.9%
Sector rank
#26
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$69.85 – $112.84
vs. $79.27 today · expected CAGR -2% – 7%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $36.22B | $39.12B | $42.25B | $45.63B | $49.28B |
| Net income | $5.07B | $5.48B | $5.91B | $6.39B | $6.90B |
| EPS | $3.95 | $4.27 | $4.61 | $4.98 | $5.37 |
| Share price (low) | $51.34 | $55.45 | $59.89 | $64.68 | $69.85 |
| Share price (high) | $82.94 | $89.58 | $96.74 | $104.48 | $112.84 |
| CAGR (low–high) | -35% / 5% | -16% / 6% | -9% / 7% | -5% / 7% | -2% / 7% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for MDT:
- Healthy free-cash-flow yield (~5.9%) funds buybacks and dividends.
- Pays a 3.6% dividend on top of any price gains.
The case against MDT:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Medtronic is a large-cap health care business growing at a mature pace, with solid profitability, and a sound balance sheet. It trades at 21.2x earnings, which our model scores Neutral (55/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.